Alluzience ® , the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe
Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1
"The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues.
As the first ready-to-use neurotoxin in Europe, Alluzience® is fit for the needs of today; it will allow me to consistently optimize results and deliver patient satisfaction with more precision. Most importantly, it will help people to feel confident in themselves again.”
Dr Joanna Czuwara, MD, PhD, Associate Professor, Department of Dermatology, Warsaw Medical University, Poland
As people age, the skin and underlying muscles play a significant role in the emergence of noticeable lines and folds, including glabellar lines between the eyebrows.2 Clostridium botulinum toxin type A (BoNT-A), the active ingredient in Alluzience®, is often used to smooth facial lines including glabellar lines.2 All currently approved BoNT-A products (or formulations) in Europe come in powder form and require reconstitution with sodium chloride before use.2 The ready-to-use liquid formulation of Alluzience® avoids any calculations and allows for more precision, meaning it has the potential to improve safety and dosing accuracy compared with powder form BoNT-A preparations.2 Alluzience® was developed using novel production technologies meaning it is free from human and animal-derived proteins such as human serum albumin and lactose.1
The European Marketing Authorization Application of Alluzience® is based on pooled data from two pivotal trials of 372 patients with moderate to severe glabellar lines who were treated with either Alluzience® (n=250) or placebo (n=122). These data demonstrated that >50% of patients reported an effect within two to three days, including 23% of patients within one day.1 An effect was demonstrated for up to six months after injection with Alluzience®.1 The responder rate at day 29 was significantly higher for patients treated with Alluzience® compared to placebo (primary endpoint) (p<0.0001).1
Additionally, patients’ level of satisfaction one month following injection showed that 85.2% of the patients receiving Alluzience® were either satisfied or very satisfied compared to 9% for placebo patients.1 The majority of adverse reactions reported with Alluzience® in clinical trials were of mild to moderate intensity and reversible.1 The most frequently reported adverse reactions were headache and injection site reactions.1
"At Galderma we pride ourselves on developing innovative products that meet today’s needs, which is underpinned by our longstanding knowledge and heritage in dermatology. We know how advantageous it is for doctors to have access to a ready-to-use liquid formulation in Alluzience®. It’s for this reason that today's news is an important milestone for both patients and healthcare professionals.”
Alexandre Brennan - Head, Global Business Unit for Aesthetics
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story.
For more information: www.galderma.com.
About Alluzience® (liquid botulinum toxin type A)
Alluzience® (liquid botulinum toxin type A) is the first ready-to-use BoNT-A liquid neuromodulator formulation to be introduced in Europe. Alluzience® should only be administered by a physician with appropriate qualifications and expertise in this treatment using the required equipment.1 Dosing and treatment intervals depend on assessment of the individual patient’s response.1 The treatment interval should be no more frequent than every three months.1 For more information, please see the Summary of Product Characteristics.1
Alluzience® is a product under license from Ipsen. Alluzience® is a registered trademark of Ipsen. Galderma has an exclusive license from Ipsen to develop, promote and distribute Alluzience® in the approved indication in Europe (excluding Czech Republic, Slovakia, Greece, Lithuania, Estonia, Latvia, Hungary).
1 Alluzience Summary of Product Characteristics.
2 Ascher B, Rzany B, Kestemont P, et al. Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo Controlled Study of a Single Treatment, Ready-to Use Toxin for Moderate-to-Severe Glabellar Lines. Aesthet Surg J. 2020;40(1):93–104.
Job code: GL-ALZ-2100026
Date of preparation: June 2021
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Lauren Starr, Head of Franchise Communications at Galderma
Phone: +41 79 771 52 45
Justine Brodie, Senior Account Manager at OPEN Health
Phone: +44 7342 092 035
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma22.6.2021 16:31:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the European Commission (EC) has granted marketing authorisation for the expanded use of DARZALEX®▼ (daratumumab) subcutaneous (SC) formulation in two new indications. The first authorisation of these new indications is for the use of daratumumab SC in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adults with newly diagnosed systemic light chain (AL) amyloidosis. This approval makes this daratumumab-based regimen the first approved therapy for AL amyloidosis in Europe. The second authorisation is for the use of daratumumab SC in combination with pomalidomide and dexamethasone (D-Pd) for the treatment of adults with multiple myeloma (MM) who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor, and have
PPG Introduces Digital Color-Matching Device for Commercial Vehicles22.6.2021 15:02:00 CEST | Press release
PPG (NYSE: PPG) today announced the introduction of its ColorReader portable digital device, which will enable customers in the commercial vehicle sector to quickly and precisely match colors to the PPG DELFLEET ONE® color palette and international standard colors. ColorReader is a BLUETOOTH®-connected device that works with a dedicated app. Available for iOS and Android tablets and smartphones, the device provides a highly accurate color match in just a few seconds. “All users have to do is download the ColorReader app, connect with their smartphone or tablet, and place ColorReader on the painted surface to scan,” said Jo Thompson, PPG color marketing manager, automotive refinish, Europe, Middle East and Africa. “ColorReader also offers a smart solution when a smartphone or tablet is not available by instantly displaying the three closest matching colors on its built-in display after scanning.” PPG recently launched ColorReader in Europe, the Middle East and Africa, and has received a
Personalis Announces NeXT Level Biomarkers Symposium22.6.2021 15:01:00 CEST | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced its inaugural event, NeXT Level Biomarkers Symposium, which will showcase novel research into emerging biomarkers using the Personalis NeXT Platform™. This event will detail the latest research from Personalis as well as a case study done in collaboration with the Parker Institute for Cancer Immunotherapy. Presentations from Personalis will focus on recently published research into HLA loss of heterozygosity, neoantigen prediction, as well as Personalis’ novel composite biomarker, the Neoantigen Presentation Score (NEOPS™). In addition, Dr. Theresa LaVallee will be presenting findings from the PRINCE trial based on data developed and analyzed in collaboration with Personalis. The agenda for NeXT Level Biomarkers Symposium will cover: Biomarker Discovery with ImmunoID NeXT Platform® Exploring HLA LOH with the DASH (Deletion of Allele-Specific HLAs) Algorithm Neoantigen Binding Prediction and Bioma
Kymeta Joins the U.S. Army’s Armored Brigade Combat Team Pilot Program22.6.2021 15:00:00 CEST | Press release
Kymeta (www.kymetacorp.com), the communications company making mobile global, announced today that it has been selected to participate in the U.S. Army’s Armored Brigade Combat Team (ABCT) satellite communications on the move (SOTM) pilot program. The program will assess communications solutions on select vehicles to enhance battlefield network and command post communications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005288/en/ The Kymeta u8 is the comprehensive connectivity solution that is available today and enables trusted, secure communications on the go and on the pause with a host of innovative features. (Photo: Business Wire) The ABCT pilot program will be led by General Dynamics Mission Systems, and Kymeta will supply eight u8 terminals for integration and testing on a variety of ABCT vehicles. Kymeta is the world’s first and only metamaterial-based SOTM terminal, and its electronically steered flat pane
Anna Biosciences Launches Pioneering Immunotherapeutic Treatment to Fight COVID-1922.6.2021 15:00:00 CEST | Press release
Anna Biosciences, a drug discovery company focused on novel therapies in immuno-oncology, virology, and neurodegenerative diseases, today announces its entry in the fight against COVID-19 with the introduction of its immunotherapy platform, Syntem. The Anna Biosciences Syntem Platform deploys engineered proprietary molecules to create synthetic immunity. Syntem’s lab-made molecules are multi-specific: they first target and flag the pathology, and then elicit an immune reaction that targets the virus or disease. Research indicates the Syntem Platform can inhibit viral infection and aid in the removal of COVID-19 infected cells. Showing promise as both a prophylactic and a treatment, there is considerable hope that in addition to supporting the broader population, immunocompromised patients will be able to safely use Syntem to prevent infection. Importantly, Syntem also exhibits high potential against COVID variants. In the case of COVID-19, and coronaviruses more generally, the Syntem P
National Arena Bucharest Completes Fast-Paced Addition of LED Stadium Lighting for UEFA EURO 202022.6.2021 15:00:00 CEST | Press release
In preparation to host UEFA EURO 2020, National Arena Bucharest has been fitted with a state-of-the-art LED lighting system – a project that was designed, shipped, and installed in just two months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005161/en/ National Arena Bucharest Completes Fast-Paced Addition of LED Stadium Lighting for UEFA EURO 2020 (Photo: Business Wire) The new LED lighting was installed to augment the stadium’s existing metal halide lights, in order to meet television broadcast standards set for by UEFA for the global event. The new lighting was designed and engineered by Musco, utilizing its Total Light Control—TLC for LED™ system. “We are now sure that we will have a spectacular EURO,” said Florin Sari, Leader Local Organizing Structure EURO 2020 Bucharest. “The win will be a stadium that will be able to host any kind of top competition from now on also.” Equally impressive as the new system’s t
Mavenir and MobiledgeX Enable Global Edge Connectivity With Deutsche Telekom22.6.2021 15:00:00 CEST | Press release
Mavenir, in collaboration with MobiledgeX and Deutsche Telekom, have demonstrated and validated the reference design for deploying cloud-native 5G User Plane Function (UPF) to support Multi-Access Edge Computing (MEC) applications, tailored to each use case need for proximity and performance. The reference design is fully cloud-native, abstracted away from underlying cloud architecture, infrastructure vendor and operating owner. “We are excited to partner with Mavenir and MobiledgeX to demonstrate dynamic cloud-native deployment of 5G Core UPF for users where it is needed. The UPF can run inside the operator’s owned network, inside a private 4G/5G network, inside the roaming network, or in the public cloud. The ability to dynamically and seamlessly orchestrate traffic across our own footprint and the footprint of others opens up the possibility for new connectivity solutions for customers,” says Alex Choi, SVP Strategy & Technology Innovation, Deutsche Telekom. A service-based, cloud-n